Related references
Note: Only part of the references are listed.Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis
Antonio Agraz-Doblas et al.
HAEMATOLOGICA (2019)
Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study
Rob Pieters et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML
Christina D. Drenberg et al.
NATURE COMMUNICATIONS (2019)
The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia
Dominique J. P. M. Stumpel et al.
EUROPEAN JOURNAL OF CANCER (2015)
Acute Lymphoblastic Leukemia in Children
Stephen P. Hunger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants
Ronald W. Stam et al.
BLOOD (2010)
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial
Rob Pieters et al.
LANCET (2007)
Phase II study of Gemcitabine in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia (ADVL0022): A Children's Oncology Group report
AL Angiolillo et al.
PEDIATRIC BLOOD & CANCER (2006)
In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype
NL Ramakers-van Woerden et al.
LEUKEMIA (2004)
Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia
RW Stam et al.
BLOOD (2003)
Nucleoside analogues and nucleobases in cancer treatment
CM Galmarini et al.
LANCET ONCOLOGY (2002)
Share Paper
